Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.34 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022533 | 0.82 | ALDH1A1 (0.42) | CHRM4ROCK2ROCK1CARM1PRMT6 | |
| SCHEMBL5481957 | 0.79 | CHRM4 (0.45) | RIPK1CHRM4ROCK2ROCK1FPR3 | |
| SCHEMBL1562512 | 0.78 | KMT2A (0.46) | KMT2AERCC1ERCC4 | |
| SCHEMBL29788838 | 0.78 | RIPK1 (0.46) | RIPK1CHRM4ROCK2ROCK1FPR3 | |
| SCHEMBL28170740 | 0.75 | RIPK1 (0.46) | RIPK1CHRM4ROCK2ROCK1FPR3 | |
| SCHEMBL17882240 | 0.74 | RIPK1 (0.54) | RIPK1CHRM4ROCK2ROCK1FPR3 | |
| SCHEMBL29912695 | 0.74 | RIPK1 (0.54) | RIPK1CHRM4ROCK2ROCK1FPR3 | |
| SCHEMBL28170731 | 0.73 | HPGD (0.44) | RIPK1CHRM4 | |
| SCHEMBL5016313 | 0.72 | MAPK1 (0.60) | KMT2A | |
| SCHEMBL17882386 | 0.71 | RIPK1 (0.47) | RIPK1CHRM4ROCK2ROCK1FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592684-B1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7375099-B2 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1592684-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-20040220222-A1 | Malonamide derivatives | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-11-04 | — | — | US | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220222-A1 | Malonamide derivatives | BACE1, BACE2, APP | RIPK1 1978/4885CHRM4 1445/4885ROCK2 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.